Business
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
-- Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells -- PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR),
About this update from Xencor, Inc.
[{"type":"text","content":"\n-- Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells --\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb®564 in healthy volunteers. XmAb564 is a potency-tuned IL-2-Fc fusion protein, engineered to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of patients with autoimmune diseases. Results will be presented in a poster titled “XmAb564, a Novel Potency-Tuned IL-2 Fc-Fusion Protein Selectively Expands Regulatory T Cells: Results from a Single Ascending-Dose Study in Healthy Adult Volunteers” at the European Congress of Rheumatology (EULAR) being held May 31 to June 3 in Milan, Italy.\n\n\n“We have previously presented that a single dose of XmAb564 was well tolerated in healthy volunteers and generates durable, dose-dependent and selective expansion of regulatory T cells. The magnitude and duration of Treg induction may be superior to other IL-2 candidates evaluated clinically and could potentially support extended multi-week dosing intervals,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “We continue to enroll patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis, and we anticipate completing dose escalation in psoriasis cohorts in early 2024.”\n\n\nThe poster is now available under \"Events & Presentations\" in the Investors section of the Company's website located at www.xencor.com.\n\n\nAbout XmAb®564 (IL-2 Fc)\n\n\nXmAb®564 is a wholly owned, monovalent, potency-tuned IL-2-Fc fusion protein, engineered to selectively activate and expand Tregs for the potential treatment of patients with autoimmune diseases. XmAb564 is engineered with reduced binding affinity for IL-2’s beta receptor (IL-2Rβ, CD122) and increased binding affinity for its alpha receptor (IL-2Rα, CD25). Xencor’s XmAb Bispecific Fc Domain additionally provides a stable protein scaffold and improves XmAb564’s pharmacologic properties, and Xencor’s Xtend™ Fc technology enhances its circulating half-life.\n\n\nAs presented in November...